SCHEMBL9923973

SCHEMBL9923973

O=S(=O)(c1ccc(-n2cccn2)cc1)N(Cc1ccc(C(F)(F)F)c(F)c1)c1nc2ccccn2c1Br

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 18/20 0.40
TP53 P04637 1/20 0.39
PTGER2 P43116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923983 0.94 TRPM8 (0.45) TRPM8TP53PTGER2
SCHEMBL9924014 0.91 TRPM8 (0.42) TRPM8TP53
SCHEMBL9923934 0.89 TRPM8 (0.46) TRPM8
SCHEMBL15631826 0.87 TP53 (0.40) TRPM8TP53PTGER2
SCHEMBL9924013 0.84 TRPM8 (0.46) TRPM8TP53
SCHEMBL9923981 0.84 TRPM8 (0.46) TRPM8
SCHEMBL9924050 0.82 TRPM8 (0.40) TRPM8TP53
SCHEMBL9924004 0.81 TP53 (0.39) TRPM8TP53
SCHEMBL9924016 0.78 TRPM8 (0.42) TRPM8TP53
SCHEMBL9924018 0.78 TRPM8 (0.46) TRPM8TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-9067935-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2015-06-30 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2014-03-27 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 US disclosed
WO-2012078994-A1 IMIDAZO [1, 2-A] PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 TRPM8 1/4885TP53 3554/4885PTGER2 293/4885
US-20140088098-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 TRPM8 1/4885TP53 3554/4885PTGER2 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.